Pulmonary Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

By

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

Egg-and-Banana Sign Has High Specificity for Pulmonary Hypertension Diagnosis

By

The "egg-and-banana" sign is a valid computed tomography marker of pulmonary hypertension.

Veno-Arterial Extracorporeal Membrane Oxygenation Improves Survival in Pulmonary Embolism

Veno-Arterial Extracorporeal Membrane Oxygenation Improves Survival in Pulmonary Embolism

By

A protocolized study including initiation of VA-ECMO may reduce mortality in patients with massive PE.

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

By

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

By

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

By

The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

By

Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

By

In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.

Perioperative Risk Assessment in a Patient With COPD

Perioperative Risk Assessment in a Patient With COPD

By

A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.

Pulmonary hypertension in heart failure with preserved ejection fraction is associated with mortality

Pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) is common in patients undergoing right heart catheterization. Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are predictors of mortality and cardiac hospitalizations in PH-HFpEF.

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

By

Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

By

Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.

Pulmonary Hypertension Mortality Following Cardiac Catheterization

Pulmonary Hypertension Mortality Following Cardiac Catheterization

By

Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.

Clinical Case: Pregnant Woman Presents With Worsening Dyspnea

Clinical Case: Pregnant Woman Presents With Worsening Dyspnea

By

A 32-year-old woman presents to the emergency department with complaints of dyspnea on exertion and near syncopal episodes.

PDE-5 Inhibitor Prescribing Trends Do Not Meet Pulmonary Hypertension Guidelines

PDE-5 Inhibitor Prescribing Trends Do Not Meet Pulmonary Hypertension Guidelines

By

Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions are inconsistent with pulmonary hypertension guidelines.

Pulmonary Arterial Hypertension Identified Via Claims-Based Algorithm

Pulmonary Arterial Hypertension Identified Via Claims-Based Algorithm

By

Patients with pulmonary arterial hypertension may be better identified with the use of a claims-based algorithm that includes ICD-9-CM codes, electronic medical records, and more.

Pulmonary Hypertension With HFpEF: Hemodynamic Markers Predict Mortality, Hospitalization

Pulmonary Hypertension With HFpEF: Hemodynamic Markers Predict Mortality, Hospitalization

Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are associated with mortality in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Hemodynamic markers of pulmonary hypertension in heart failure with preserved ejection fraction are associated with mortality

Transpulmonary gradient, pulmonary vascular resistance, and diastolic pulmonary gradient are predictors of mortality and cardiac hospitalizations in pulmonary hypertension associated with heart failure with preserved ejection fraction.

Right Atrium Enlargement Predicts Supraventricular Arrhythmia Risk in PAH

Right Atrium Enlargement Predicts Supraventricular Arrhythmia Risk in PAH

By

Right atrium enlargement may predict the risk for supraventricular arrhythmias in patients with pulmonary arterial hypertension.

Long-Term Prognosis in Women vs Men With Pulmonary Arterial Hypertension

Long-Term Prognosis in Women vs Men With Pulmonary Arterial Hypertension

By

Women with pulmonary arterial hypertension may have better long-term prognoses compared with men, potentially because of improvements in right ventricular function.

Pulmonary Embolism Rule-Out Criteria Can Identify Thromboembolic Events

Pulmonary Embolism Rule-Out Criteria Can Identify Thromboembolic Events

By

A 3-month risk for a thromboembolic event was assessed using a pulmonary embolism rule-out criteria strategy and compared with a conventional strategy in patients with a low clinical probability of pulmonary embolism.

Pulmonary Embolism With Low Mortality Risk Treated in Outpatient Setting

Pulmonary Embolism With Low Mortality Risk Treated in Outpatient Setting

By

Acute pulmonary embolism may be managed in an outpatient setting when the patient has a low risk for mortality.

Idiopathic PAH-Associated Hypoxemia Linked to Poor Survival, Increased Comorbidities

Idiopathic PAH-Associated Hypoxemia Linked to Poor Survival, Increased Comorbidities

By

Hypoxemia is associated with reduced survival in patients with idiopathic or heritable pulmonary arterial hypertension.

Peak Circulatory Power Is a Potent Predictive Tool in Idiopathic PAH

Peak Circulatory Power Is a Potent Predictive Tool in Idiopathic PAH

By

Peak circulatory may provide reliable prognostic information in patients with idiopathic pulmonary arterial hypertension.

6MWT Clinically Relevant and Appropriate Prognostic Tool for PAH

6MWT Clinically Relevant and Appropriate Prognostic Tool for PAH

By

The 6MWT is a clinically relevant and appropriate target for patients with pulmonary arterial hypertension.

Pulmonary Hypertension Treatments Targeting NO Pathway Compared for Safety

Pulmonary Hypertension Treatments Targeting NO Pathway Compared for Safety

By

Several drugs may demonstrate different safety profiles and side effects that warrant a change in treatment for individuals with pulmonary hypertension.

Two 6-Minute Walk Tests Recommended for Suspected Pulmonary Hypertension

Two 6-Minute Walk Tests Recommended for Suspected Pulmonary Hypertension

By

To minimize the "learning effect" and improve accuracy, patients with suspected pulmonary hypertension should undergo two 6-minute walk tests.

Global Pulmonary Vascular Remodeling and Pulmonary Hypertension in Heart Failure

Global Pulmonary Vascular Remodeling and Pulmonary Hypertension in Heart Failure

By

Researchers discovered an association between global pulmonary vascular remodeling and pulmonary hypertension in patients with heart failure.

Assessment of Ambrisentan in Pulmonary Arterial Hypertension

Assessment of Ambrisentan in Pulmonary Arterial Hypertension

By

In a postmarketing surveillance study, ambrisentan demonstrated tolerability and potential effectiveness for pulmonary arterial hypertension treatment.

Pilot Study to Assess Effectiveness of Milrinone in Congenital Diaphragmatic Hernia

Pilot Study to Assess Effectiveness of Milrinone in Congenital Diaphragmatic Hernia

By

A pilot study will assess the effectiveness of milrinone in a small group of infants born with congenital diaphragmatic hernia.

Sign Up for Free e-Newsletters